CLINICAL_TRIALS
trial_result
· 2026-06-02
Clinical Trial Update: Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) [Phase 3]
Summary
Phase 3 trial update on V503 evaluating efficacy, immunogenicity, and safety in Chinese women aged 20-45 with papillomavirus infections.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING